Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults

20260 citationsJournal Article

Authors

Nicholas Wettersten · University of San Diego

Abstract

In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF, compared with semaglutide, with a similar safety profile.

Topics & Keywords

Diabetes Treatment and Management Bariatric Surgery and Outcomes Pharmacology and Obesity Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.70721

Field-Weighted Citation Impact: 0.00